Zurich Cantonal Bank’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Zurich Cantonal Bank’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-17,511	Closed	-$45.4K	–	2804
2023 Q2	$45.4K	Buy	17,511 +5,995	+52%	+$21.4K	﹤0.01%	2639
2023 Q1	$47K	Hold	11,516	–	–	﹤0.01%	2612
2022 Q4	$57.8K	Buy	11,516 +3,476	+43%	+$21.8K	﹤0.01%	2555
2022 Q3	$105K	Hold	8,040	–	–	﹤0.01%	2184
2022 Q2	$103K	Hold	8,040	–	–	﹤0.01%	2222
2022 Q1	$123K	Sell	8,040 -1,928	-19%	-$30.1K	﹤0.01%	2185
2021 Q4	$177K	Buy	9,968 +7,907	+384%	+$152K	﹤0.01%	2152
2021 Q3	$43K	Buy	2,061 +3	+0.1%	+$66	﹤0.01%	2661
2021 Q2	$41K	Buy	2,058 +85	+4%	+$1.99K	﹤0.01%	2496
2021 Q1	$57K	Buy	+1,973	New	+$55.2K	﹤0.01%	2357

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zurich Cantonal Bank's NGM Position: Q3 2023 in Review

Zurich Cantonal Bank sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 17,511 shares — an estimated $45.4K sold.

Zurich Cantonal Bank first reported a position in NGM in Q1 2021 and held it in 10 quarters. The position peaked at $177K in Q4 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

Zurich Cantonal Bank reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Zurich Cantonal Bank sold 17,511 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $45.4K.
Zurich Cantonal Bank first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Zurich Cantonal Bank's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $177K in Q4 2021.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Zurich Cantonal Bank's 13F filing for Q3 2023, filed 25 Oct 2023.